TNF and metabolic dysfunction-associated steatohepatitis: These reports suggest that ipragliflozin might have attenuated NASH development through not only the improvement of hyperglycemia by inducing the urinary excretion of glucose but also by modulation of miR-19b-3p to inhibit IL-6 and TNF-α expression.